Drugs / MPER-656 Liposome Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03934541 | Aug 2019 → Feb 2021 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MPER-656 Liposome Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03934541 ↗ |
| Modality | Vaccine | “MPER-656 liposome vaccine” NCT03934541 ↗ |
| Route | Intramuscular | “Administered by intramuscular injection” NCT03934541 ↗ |